Gilead Sciences Inc.
GILDNASDAQAlpha Score of 40 reflects weak overall profile with moderate value, poor quality, moderate sentiment. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Gilead Sciences Maintains Quality Metrics Amidst Significant Earnings Growth Recovery
Apr 15, 2026Gilead Sciences closed today reflecting a mixed market profile as investors weigh substantial earnings recovery against moderate top-line expansion. The company reported a massive year-over-year EPS growth rate of 1903.1 percent, contrasting with a modest 2.4 percent revenue growth figure. With a current P/E ratio of 20.99 and a robust net margin of 28.9 percent, the firm demonstrates strong operational efficiency. Gilead currently trades within its 52-week range of $96.91 to $155.8, positioning it in the middle of its annual volatility band. The Alpha Score of 59.8 is anchored by a high quality sub-score of 75.9, which highlights stable fundamental health. Momentum remains moderate at 63.2, while value and sentiment sub-scores of 47.7 and 50 respectively suggest a neutral market outlook. These metrics indicate that while the company has successfully improved its bottom-line performance, market participants are waiting for more consistent revenue acceleration to drive further valuation expansion. Investors should monitor upcoming quarterly revenue guidance to see if the recent earnings momentum translates into sustained top-line growth.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 27, 26 | O'Day Daniel Patrick | Chairman & CEO | SELL | 10.0K | $1.4M |
| Mar 16, 26 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 3.0K | $433K |
| Mar 16, 26 | Dickinson Andrew D | Chief Financial Officer | SELL | 3.0K | $433K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 6.06M | $743.46M | NEW |
| Renaissance Technologies Jim Simons (founder) | 2.79M | $342.29M | NEW |
| Marshall Wace | 794K | $97.42M | NEW |
| D.E. Shaw David Shaw | 300K | $36.87M | NEW |
| Point72 Steve Cohen | 60K | $7.32M | NEW |
| Hussman Investment Trust John Hussman | 11K | $1.46M | -29% |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Jared Moskowitz D-FL | 2026-05-06 | purchase | $1k – $15k |
| Valerie Hoyle D-OR | 2025-09-23 | sale | $1k – $15k |
| Marjorie Taylor Greene GA | 2025-05-05 | purchase | $1k – $15k |
| Carol Devine Miller WV | 2025-03-10 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ | 2025-03-07 | purchase | $1k – $15k |
| Valerie Hoyle D-OR | 2024-10-29 | purchase | $1k – $15k |
| Greg Stanton D-AZ | 2023-09-26 | purchase | $1k – $15k |
| Daniel Goldman NY | 2023-07-12 | sale | $15k – $50k |
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs in infectious diseases, oncology, and other therapeutic areas across the United States, Europe, and international markets. Its portfolio centers on HIV treatments, including leading products like Biktarvy, Genvoya, Descovy, Odefsey, Sunlenca, and Yeztugo, the world's first twice-yearly HIV prevention therapy. The company also offers therapies for viral hepatitis such as Epclusa, Harvoni, Vemlidy, and Viread, alongside Veklury for COVID-19. In oncology and cell therapy, Gilead provides Yescarta, Tecartus, and Trodelvy for various cancers, as well as Livdelzi for primary biliary cholangitis. These products target life-threatening conditions in virology, liver diseases, hematology, inflammation, and respiratory areas, serving patients through innovative antiviral regimens, CAR-T cell therapies, and antibody-drug conjugates. Founded in 1987 and headquartered in Foster City, California, Gilead Sciences Inc. plays a pivotal role in advancing treatments for chronic and infectious diseases globally.
Earnings calendar coming soon. Subscribe to get notified when GILD reports next.
Get earnings alerts →